12/7/2022 7:14:10 AM
Replimune Announces Positive Initial Data From Anti-PD1 Failed Melanoma Cohort Of IGNYTE Clinical Trial
10/7/2022 8:08:52 AM
Replimune Obtains $200 Mln Non-dilutive Term Loan Facility From Hercules Capital
5/19/2022 8:40:00 AM
Replimune Q4 Net Loss $31.7 Mln Vs Loss Of $21.5 Mln Last Year
1/5/2021 8:25:30 AM
Replimune Doses First Patient In Phase 1 Clinical Trial Of RP3
4/24/2019 9:36:27 PM
Wedbush Starts Replimune Group Inc. (REPL) At Outperform With $24 Price Target